drugset / Trial / NCT03957720

The Individual Therapy for Patients With Wilson's Disease

NCT03957720

Non-randomizedSequentialSingle-blindTreatment

Summary

Based on the genotype characteristics and genotype-phenotype-treatment prognosis data of Chinese WD patients, this study intends to further optimize the treatment regimen of Chinese WD patients and formulate individualized treatment regimens for each genotype, so as to further improve the prognosis of patients.

Timeline

Start
2019-03-15
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 2,3-dimercapto-1-propanesulfonic acid Small molecule 500 mg
Subject 2,3-dimercapto-1-propanesulfonic acid Small molecule 1000 mg
Subject Succimer Small molecule 35 mg/kg
Subject Succimer Small molecule 750 mg
Subject Succimer Small molecule 1000 mg
Subject Zinc gluconate Small molecule 140 mg
Subject Zinc gluconate Small molecule 210 mg
Subject penicillamine Unknown 250 mg
Subject penicillamine Unknown 1500 mg

Indications